GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence - Summary - MDSpire

GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence

  • By

  • Petra Sedova

  • Michal Vrablík

  • Petr Kala

  • Petr Ošťádal

  • Aleš Tichopád

  • Aleš Tomek

  • Robert Mikulik

  • Gleb Donin

  • Simona Littnerová

  • Julia Anna Kent

  • Jiří Jarkovsky

  • Virend K Somers

  • Robert D Brown

  • January 7, 2026

  • 0 min

Share

Objective:

To evaluate the real-world effectiveness of GLP-1 receptor agonist therapy on cardiovascular outcomes in patients with Type 2 diabetes after myocardial infarction or ischaemic stroke.

Key Findings:
  • GLP-1RA therapy was initiated in only ∼2% of MI and stroke survivors with T2D.
  • Among MI survivors with T2D, GLP-1RA use was associated with a 30% lower risk of MACE and 40-45% lower risk of all-cause and cardiovascular death.
  • Among stroke survivors with T2D, GLP-1RA use was associated with a similar reduction in MACE and mortality risks.
Interpretation:

GLP-1RA therapy after MI or stroke in T2D is linked to significantly lower risks of adverse cardiovascular outcomes and mortality, yet utilization remains low, particularly among women and older adults.

Limitations:
  • Low initiation rates of GLP-1RA therapy among eligible patients.
  • Potential disparities in access to treatment based on age and sex.
Conclusion:

Starting GLP-1RA after a cardiovascular event is associated with improved outcomes, highlighting the need for better implementation of these therapies in secondary prevention.

Original Source(s)

GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence

  • by Petra Sedova, Michal Vrablík, Petr Kala, Petr Ošťádal, Aleš Tichopád, Aleš Tomek, Robert Mikulik, Gleb Donin, Simona Littnerová, Julia Anna Kent, Jiří Jarkovsky, Virend K Somers, Robert D Brown

  • January 7, 2026

Related Content

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Acupuncture for post-stroke recovery: a retrospective cohort study on motor function and quality of life

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients